Jennifer L.Bachorik Ph.D. (Jen)


New York + 1.212.326.3691

Jen Bachorik focuses her practice on client counseling and preparation and prosecution of patent applications in the life science, biotechnology, and pharmaceutical fields. She has experience with a variety of technologies related to neurodegenerative disease, immunotherapy, virology, genetics, microbiology, stem cells, gene therapy, RNA (ribonucleic acid) biochemistry and biology, transdermal drug delivery, and personalized medicine. She performs patent landscape analyses to assess freedom-to-operate, patentability, and invalidity issues, and her experience also includes IP litigation and inter partes review (IPR) proceedings.

Prior to joining Jones Day in 2017, Jen was an associate at an international law firm. She worked full-time as a patent agent while attending law school in the evenings, where she received distinctions for academic performance and for best papers in antitrust and legal research and writing courses.

Before law school, Jen was a postdoctoral research associate in the Howard Hughes Medical Institute (HHMI) lab of Dr. Gideon Dreyfuss at the University of Pennsylvania. In this role she investigated the biochemical basis of the neurodegenerative disease Spinal Muscular Atrophy (SMA). Jen and her colleagues were awarded the FEBS Letters Most Cited Paper 2008 Award from Elsevier, a leading provider of scientific, technical, and medical books and journals. Her Ph.D. thesis work at the University of Wisconsin was conducted in the HHMI lab of Dr. Judith Kimble and focused on deciphering the role of a family of RNA-binding proteins in C. elegans germline development.


  • Astellas and Agensys prosecute patent portfolios for novel monoclonal antibody and antibody-drug conjugate immunotherapeutics useful for certain cancer treatmentsJones Day represents Astellas Pharma Inc. and its subsidiary Agensys, Inc. in prosecuting their worldwide patent portfolios related to novel monoclonal antibody and antibody-drug conjugate (ADC) immunotherapeutics for use in the treatment of a variety of cancer indications, including PADCEV®, an ADC approved by the FDA in 2019 for the treatment of metastatic bladder cancer.